Regulations.gov document
Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry; Availability
Notice · FDA-2020-D-2101 · posted Oct 24, 2022
Key facts
| Document ID | FDA-2020-D-2101-0042 |
|---|---|
| Title | Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2020-D-2101 |
| Posted | Oct 24, 2022 |
| Federal Register citation | 87 FR 64234 |
| FR document number | 2022-23057 |
| Comment period opens | Oct 24, 2022 |
| Effective date | Oct 24, 2022 |
At a glance
- 1–9 Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: